Objective Resolvins are produced by the catabolism of polyunsaturated fatty acids (PUFAs) and play vital roles in inflammation resolution. Resolvins have been associated with autoimmune disorders. This study aimed to measure the level of Resolvin D1 (RVD1) in the serum of Hashimoto's thyroiditis (HT) patients and healthy controls (HCs) and to further analyse its correlation with thyroid autoantibodies and inflammatory factors. Methods Sixty-three participants were recruited, namely, 30 untreated HT patients and 33 sex- and age-matched HCs. Serum RVD1 and inflammatory chemokine (MCP-1 and IP-10) levels were measured by ELISA according to the manufacturer’s protocol. Serum total T3 (TT3), TT4, free T3 (FT3), FT4, thyroglobulin antibody (TgAb), thyroid peroxidase antibody (TPOAb) and thyroid-stimulating hormone (TSH) levels were measured using an electrochemiluminescence immunoassay. Thyroid homeostasis parameters, including the thyroid secretory capacity (SPINA-GT), the total deiodinase activity (SPINA-GD), Jostel’s TSH index (TSHI) and the thyrotroph thyroid hormone sensitivity index (TTSI), were calculated. Results Serum RVD1 levels in HT patients (134.76, 85.35–201.36 pg/mL) were significantly lower than those in HCs (187.64, 131.01–326.85 pg/mL) (P=0.004). As the TPOAb level increased, the RVD1 level showed a decreasing trend (P for trend=0.002). Both multinomial and ordinal logistics analyses revealed that serum RVD1 levels were negatively correlated with TPOAb levels in the adjusted models. Moreover, RVD1 showed a negative correlation with the inflammatory chemokine IP-1 0 (r=–0.276, P=0.034), TSHI (r=–0.269, P=0.036) and TTSI (r=–0.277, P=0.031). Conclusions Thyroid autoimmunity may be associated with low levels of RVD1. Decreased RVD1 levels indicate impaired resolution of inflammation in HT patients.

中文翻译：

---

专门的促分解介质 Resolvin D1 在桥本甲状腺炎中的作用

目的 Resolvins 由多不饱和脂肪酸 (PUFA) 的分解代谢产生，在炎症消退中起重要作用。Resolvins与自身免疫性疾病有关。本研究旨在测量桥本甲状腺炎（HT）患者和健康对照者（HCs）血清中Resolvin D1（RVD1）的水平，并进一步分析其与甲状腺自身抗体和炎症因子的相关性。方法 招募了 63 名参与者，即 30 名未经治疗的 HT 患者和 33 名性别和年龄匹配的 HC。根据制造商的方案，通过 ELISA 测量血清 RVD1 和炎症趋化因子（MCP-1 和 IP-10）水平。血清总 T3 (TT3)、TT4、游离 T3 (FT3)、FT4、甲状腺球蛋白抗体 (TgAb)、使用电化学发光免疫测定法测量甲状腺过氧化物酶抗体 (TPOAb) 和促甲状腺激素 (TSH) 水平。计算甲状腺稳态参数，包括甲状腺分泌能力（SPINA-GT）、总脱碘酶活性（SPINA-GD）、Jostel 促甲状腺激素指数（TSHI）和促甲状腺激素敏感性指数（TTSI）。结果 HT 患者血清 RVD1 水平（134.76, 85.35–201.36 pg/mL）显着低于 HCs（187.64, 131.01–326.85 pg/mL）（P=0.004）。随着 TPOAb 水平升高，RVD1 水平呈下降趋势（趋势 P = 0.002）。多项和序数逻辑分析均显示血清 RVD1 水平与调整模型中的 TPOAb 水平呈负相关。此外，RVD1 与炎症趋化因子 IP-1 0 呈负相关（r=–0. 276, P=0.034), TSHI (r=–0.269, P=0.036) 和 TTSI (r=–0.277, P=0.031)。结论甲状腺自身免疫可能与低水平的RVD1有关。降低的 RVD1 水平表明 HT 患者的炎症消退受损。